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Abstract
Background: Vascular adhesion protein-1 (VAP-1) is an adhesion molecule that plays a key role in recruiting
leucocytes into sites of inflammation. We have previously shown that
68Gallium-labelled VAP-1-targeting peptide
(
68Ga-DOTAVAP-P1) is a positron emission tomography (PET) imaging agent, capable of visualising inflammation in
rats, but disadvantaged by its short metabolic half-life and rapid clearance. We hypothesised that prolonging the
metabolic half-life of
68Ga-DOTAVAP-P1 could further improve its imaging characteristics. In this study, we
evaluated a new analogue of
68Ga-DOTAVAP-P1 modified with a mini-polyethylene glycol (PEG) spacer (
68Ga-
DOTAVAP-PEG-P1) for in vivo imaging of inflammation.
Methods: Whole-body distribution kinetics and visualisation of inflammation in a rat model by the peptides
68Ga-
DOTAVAP-P1 and
68Ga-DOTAVAP-PEG-P1 were evaluated in vivo by dynamic PET imaging and ex vivo by measuring
the radioactivity of excised tissues. In addition, plasma samples were analysed by radio-HPLC for the in vivo stability
of the peptides.
Results: The peptide with the mini-PEG spacer showed slower renal excretion but similar liver uptake as the
original peptide. At 60 min after injection, the standardised uptake value of the inflammation site was 0.33 ± 0.07
for
68Ga-DOTAVAP-P1 and 0.53 ± 0.01 for
68Ga-DOTAVAP-PEG-P1 by PET. In addition, inflammation-to-muscle ratios
were 6.7 ± 1.3 and 7.3 ± 2.1 for
68Ga-DOTAVAP-P1 and
68Ga-DOTAVAP-PEG-P1, respectively. The proportion of




Conclusion: The eight-carbon mini-PEG spacer prolonged the metabolic half-life of the
68Ga-DOTAVAP-P1 peptide,
leading to higher target-to-background ratios and improved in vivo PET imaging of inflammation.
Keywords: gallium-68, inflammation imaging, mini-PEG spacer, positron emission tomography, vascular adhesion
protein-1
Background
In vivo imaging of inflammation is a demanding task,
and novel molecular imaging targets are called for. The
gold standard in nuclear medicine is the radiolabelling
of white blood cells, which is both time consuming and
potentially hazardous for the technical personnel.
Vascular adhesion protein-1 (VAP-1) is an inflamma-
tion-inducible endothelial adhesion protein involved in
the leucocyte trafficking from the blood stream into the
tissues. VAP-1 is stored in intracellular granules within
endothelial cells. However, upon inflammation, it is
rapidly translocated to the endothelial cell surface, for
example, in the synovial tissue in rheumatoid arthritis
a n da tt h es i t eo fi s c h e m i cr e p e r f u s i o ni n j u r y[ 1 , 2 ] .
Therefore, VAP-1 is both an optimal candidate for anti-
inflammatory therapy and a potential target for in vivo
imaging of inflammation. This approach may open new
opportunities for diagnosing, therapy planning and mon-
itoring of the treatment efficacy, as well as for the drug
discovery and development processes [3-6].
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provided the original work is properly cited.Peptide-based imaging agents are small molecules that
possess favourable properties such as rapid diffusion in
target tissue, rapid clearance from the blood circulation
and non-target tissues, easy and low-cost synthesis, and
low toxicity and immunogenicity. We are particularly
interested in developing radiolabelled peptides for VAP-
1 targeting for the purposes of in vivo imaging of leuco-
cyte trafficking. The linear peptide, VAP-P1, has been
characterised by Yegutkin et al. and proven to bind the
enzymatic groove of VAP-1 and dose-dependently inhi-
bit VAP-1-dependent lymphocyte rolling and firm adhe-




68Ga-DOTAVAP-P1) is able to delineate
inflammation in rats by a VAP-1-specific way using
positron emission tomography (PET) [8-10]. Disadvanta-
geously, the
68Ga-DOTAVAP-P1 peptide has relatively
short plasma half-life and very rapid clearance by the
kidneys to the urine.
PEGylation, the process by which polyethylene glycol
(PEG) chains or its derivatives, e.g., mini-PEGs are
attached to a peptide, has been used for modifying the
properties of radiolabelled compounds, such as antibo-
dies and peptides, in order to improve their imaging
characteristics. The goal of PEGylation is mainly to
improve the tracer’s kinetics and distribution pattern by
increasing its metabolic half-life and by lowering its
non-specific binding. By increasing the molecular mass
of the peptide and by shielding it from proteolytic
enzymes, PEGylation may modify its biodistribution and
pharmacokinetics [11]. Thus, the method could over-
come the above mentioned shortcomings. However,
because PEGylation may also have unfavourable effects,
such as inhibition of receptor binding and reduction of
target-to-background ratio, its impact must be carefully
evaluated for a new peptide.
We hypothesised that prolonging the metabolic half-
life of
68Ga-DOTAVAP-P1 would further improve its
potential for in vivo imaging of inflammation. In this




in vivo PET imaging of inflammation.
Methods
68Ga-DOTA-peptides
The DOTA-conjugated peptides were purchased from
Almac Sciences (By Gladsmuir, Scotland, UK), ABX
advanced biochemical compounds GmbH (Radeberg,
Germany) and NeoMPS (Strasbourg, France).
Linear 9-amino acid DOTA-chelated peptide
(GGGGKGGGG) with and without a PEG linker (8-
amino-3,6-diooxaoctanoyl, PEG derivative, MW 145.16
Da) between the DOTA and the N terminal amino acid
was labelled with





68Ga was obtained in the form of
68GaCl3 from a
68Ge/
68Ga generator (Cyclotron Co.,
Obninsk, Russia) by elution with 0.1 M HCl. The
68GaCl3 eluate (500 μl) was mixed with sodium acetate
(18 mg; Sigma-Aldrich, Seelze, Germany) to give a pH
of approximately 5.5. Then, DOTA-peptide (35 nmol)
was added and the mixture was incubated at 100°C for
20 min. No further purification was needed.
The radiochemical purity was determined by reversed-
phase HPLC (μBondapak C18, 7.8 × 300 mm
2,1 2 5Å ,
10 μm; Waters Corporation, Milford, MA, USA). The
HPLC conditions for
68Ga-DOTAVAP-P1 have been
described previously [9]. The HPLC conditions for
68Ga-
DOTAVAP-PEG-P1 were slightly different and as fol-
lows: flow rate = 4 ml/min, l =2 1 5n m ,A =2 . 5m M
trifluoroacetic acid, B = acetonitrile and C = 50 mM
phosphoric acid. Linear A/B/C gradient was 100/0/0 for
0 to 3 min, 40/60/0 for 3 to 9 min, and 0/0/100 for 9 to
16 min. The radio-HPLC system consisted of LaChrom
instruments (Hitachi; Merck, Darmstadt, Germany):
pump L7100, UV detector L-7400 and interface D-7000;
an on-line radioisotope detector (Radiomatic 150 TR,
Packard, Meriden, CT, USA); and a computerised data
acquisition system.
In vitro stability and solubility
The in vitro stability of the
68Ga-labelled peptides was
evaluated in human and rat plasma. Several samples
were taken during the 4-h incubation period at 37°C.
Proteins from plasma samples were precipitated with
10% sulphosalicylic acid (1:1 v/v), centrifuged at 3,900 ×
g for 3 min at 4°C, and filtered through 0.45-μmM i n i s -
pike filter (Waters Corporation). The filtrate was ana-
lysed by radio-HPLC.
The octanol-water distribution coefficient, logD,o f
the
68Ga-DOTA-peptides was determined using the
following procedure. Approximately 5 kBq of
68Ga-
labelled peptide in 500 μl of phosphate-buffered saline
(PBS, pH 7.4) was added to 500 μl of 1-octanol. After
the mixture had been vortexed for 3 min, it was centri-
fuged at 12,000 × g for 6 min, and 100-μl aliquots of
both layers were counted in a gamma counter (1480
Wizard 3″ Gamma Counter; EG&G Wallac, Turku,
Finland). The test was repeated three times. The logD
was calculated as = log10 (counts in octanol/counts in
PBS).
Animals
All animal experiments were approved by the Lab-Ani-
mal Care & Use Committee of the State Provincial
Office of Southern Finland and carried out in compli-
ance with the Finnish laws relating to the conduct of
animal experimentation.
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f r o mH a r l a n ,H o r s t ,T h eN e t h e r l a n d s .T w e n t y - f o u r
hours before the PET studies, turpentine oil (Sigma-
Aldrich; 0.05 ml per rat) was injected subcutaneously
into their neck area in order to induce a sterile inflam-
mation [10]. Six rats were PET imaged and additional
eight animals were used for in vivo metabolite analyses.
PET imaging and ex vivo biodistribution
The whole-body distribution and kinetics of
68Ga-
DOTAVAP-P1 (n =3 )a n d
68Ga-DOTAVAP-PEG-P1 (n
= 3) in rats harbouring a sterile inflammation were stu-
died with a high-resolution research tomograph (Sie-
mens Medical Solutions, Knoxville, TN, USA). The rats
were anaesthetised with isoflurane (induction 3%, main-
tenance 2.2%). Two rats were imaged at the same time,
and they were kept on a warm pallet during the imaging
procedure. Following a 6-min transmission for attenua-
tion correction, the rats were intravenously (i.v.) injected
with
68Ga-DOTAVAP-P1 (15.8 ± 3.0 MBq, 19.4 ± 0.0
μg, 19.6 ± 0.0 nmol) or with
68Ga-DOTAVAP-PEG-P1
(17.7 ± 1.6 MBq, 21.0 ± 1.3 μg, 18.5 ± 1.1 nmol) as a
bolus via a tail vein using a 24-gauge cannula (BD Neo-
flon, Becton Dickinson Infusion Therapy AB, Helsing-
borg, Sweden). Dynamic imaging lasting for 60 min
started at the time of injection. The data acquired in list
mode were iteratively reconstructed with a 3-D ordered
subsets expectation maximisation algorithm with 8 itera-
tions, 16 subsets and a 2-mm full-width at half-maxi-
mum post-filter into 5 × 60 s and 11 × 300 s frames.
Quantitative analyses were performed by drawing
regions of interest (ROI) on the inflammatory foci, mus-
cle (hind leg), heart, kidney, liver and urinary bladder.
Time-activity curves (TACs) were extracted from the
corresponding dynamic images (Vinci software, version
2.37; Max Planck Institute for Neurological Research,
Cologne, Germany). The average radioactivity concen-
trations in the ROIs (kilobecquerels per millilitre) were
used for further analyses. The uptake was reported as
standardised uptake value (SUV), which was calculated
as the radioactivity of the ROI divided by the relative
injected radioactivity expressed per animal body weight.
The radioactivity remaining in the tail was compensated.
After the PET imaging, the animals were sacrificed.
Samples of blood, urine and various organs were col-
lected, weighed and measured for radioactivity using the
gamma counter (Wizard, EG&G Wallac). The results
were expressed as SUVs.
Blood analyses
Blood samples (0.2 ml of each) were drawn at 5, 10, 15,
30, 45, 60 and 120 min after injection of
68Ga-DOTA-
peptides into heparinised tubes (Microvette 100; Sar-
stedt, Nümbrecht, Germany). Radioactivity of whole
blood was measured with the gamma counter (Wizard,
EG&G Wallac). Plasma was separated by centrifugation
(2,200 × g for 5 min at 4°C), and plasma radioactivity
was measured. The ratio of radioactivity in blood versus
plasma was calculated. To determine plasma protein
binding, proteins were precipitated with 10% sulphosa-
licylic acid, and the radioactivity in protein precipitate
and supernatant was measured. The plasma supernatant
was further analysed by radio-HPLC in order to evaluate
the in vivo stability of the
68Ga-labelled peptides.
In vivo stability data were used in order to generate




further used for the calculation of pharmacokinetic
parameters. The area under curve (AUC) of the plasma
TAC from 0 to infinity was calculated using a non-com-
partmental analysis employing the trapezoidal rule. The
clearance (CL) of the
68Ga-labelled peptides after a sin-
gle intravenous bolus dose was calculated by dividing
the injected dose by the AUC. The plot of the natural
logarithm of parent tracer concentration against time
after bolus injection became linear in the end phase, as
the tracer was eliminated according to the laws of first-
order reaction kinetics. The elimination rate constant
(kel) was calculated as the negative slope of the linear
part of the plot. The plasma elimination half-life (t1/2)
was calculated as t1/2 =l n ( 2 ) / kel. The metabolic half-
lives of the
68Ga-DOTA-peptides were calculated
according to the results of radio-HPLC, i.e. the time
point when 50% of the total radioactivity is still bound
to the intact peptide.
Statistical analyses
All the results are expressed as means ± standard devia-
tion (SD) and range. The correlations between PET ima-
ging and ex vivo measurement values were evaluated
using linear regression analysis. Inter-group comparisons
were made using an unpaired t test. Statistical analyses
were conducted using Origin 7.5 software (Microcal,
Northampton, MA, USA). A P value less than 0.05 was
considered as statistically significant.
Results
In vitro studies
The radiochemical purities of
68Ga-DOTAVAP-P1 and
68Ga-DOTAVAP-PEG-P1 were 97 ± 1% and 99 ± 1%,
and specific radioactivities 2.27 ± 0.47 and 2.55 ± 0.45




± 0.1 and 6.7 ± 0.1 min, respectively. The retention time
for free gallium was approximately 12 min, and it eluted
only with phosphoric acid. The in vitro stabilities of
68Ga-DOTAVAP-P1 and
68Ga-DOTAVAP-PEG-P1 were
very similar. The amounts of unchanged peptide after
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Page 3 of 7the 4-h incubation in human or rat plasma were 88 ±
3% and 82 ± 11% for
68Ga-DOTAVAP-P1 and 89 ± 8%
and 90 ± 6% for
68Ga-DOTAVAP-PEG-P1, respectively.
Both peptides were highly hydrophilic; logD was -3.30
for
68Ga-DOTAVAP-P1 and -3.50 for
68Ga-DOTAVAP-
PEG-P1.
PET studies with rat model of inflammation
Both peptides were capable of visualising inflammatory
foci from surrounding tissues by PET imaging (Figure
1a). The inflammation uptakes expressed as SUVs were
0.33 ± 0.07 (range, 0.26 to 0.40) and 0.53 ± 0.01 (range,
0.42 to 0.60) for
68Ga-DOTAVAP-P1 and
68Ga-DOTA-
VAP-PEG-P1, respectively, at 60 min after injection.
Inflammation-to-muscle ratios at 60 min after injection
w e r e6 . 7±1 . 3( r a n g e ,5 . 2t o7 . 5 )a n d7 . 3±2 . 1( r a n g e ,
5.6 to 9.7) for
68Ga-DOTAVAP-P1 and
68Ga-DOTA-




foci were quite fast, and the peak radioactivity was
reached within 20 min for both peptides. On the aver-
age, the inflammation uptake of
68Ga-DOTAVAP-PEG-
P1 was 59% higher than that of
68Ga-DOTAVAP-P1,
and the difference was statistically significant (P =
0.047). According to the whole-body dynamic PET ima-
ging,
68Ga-DOTAVAP-PEG-P1 showed slower renal
excretion to urine but otherwise rather similar
distribution kinetics as the original peptide
68Ga-DOTA-
VAP-P1 (Figure 1b, c, d, e).
The PET imaging results were verified by ex vivo mea-
surements (Figure 2). Linear regression analysis showed
reasonable correlation between in vivo PET and ex vivo
tissue samples (R =0 . 5 8 ,P = 0.023 for
68Ga-DOTA-
VAP-P1 and R =0 . 8 0 ,P < 0.001 for
68Ga-DOTAVAP-
PEG-P1). When the tissue uptakes of
68Ga-DOTAVAP-
P1 and
68Ga-DOTAVAP-PEG-P1 were compared, the
inflammation, lung, small intestine, skin and urinary
bladder radioactivities were significantly different.
Although the PET and ex vivo methods correlate well,
there are some discrepancies between the results. For
example, in the PET image analysis, the urine and blood
of kidney are included in the “kidney” ROI, whereas for
ex vivo measurement, the excised tissue samples are
dotted dry on a paper. Since the radioactivity of urine is
extremely high, the in vivo kidney SUV is higher than
that of ex vivo.
The blood-plasma ratios and the plasma free fractions
(fp), i.e. the fraction of total radioactivity in plasma that
is unbound to plasma proteins, were 1.3 ± 0.1 and 0.84
±0 . 0 4f o r
68Ga-DOTAVAP-P1 and 1.3 ± 0.1 and 0.86 ±
0.02 for




68Ga-DOTAVAP-P1. The proportions of
unchanged peptides in rat plasma at 60 and 120 min
Figure 1 PET images and time-activity curves.( a) Representative coronal PET images of Sprague-Dawley rats with sterile turpentine oil-
induced inflammation as a sum image of 10 to 60 min after i.v. injection of
68Ga-DOTAVAP-P1 (13.8 MBq) or
68Ga-DOTAVAP-PEG-P1 (17.5 MBq).
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68Ga-
DOTAVAP-P1 and 76 ± 18% and 49 ± 6% for
68Ga-




VAP-PEG-P1 were 24 and 125 min, respectively. Based
on in vivo plasma measurements,
68Ga-DOTAVAP-
PEG-P1 showed significantly slower kel and total CL and
larger AUC values. In addition,
68Ga-DOTAVAP-PEG-
P1 had a longer elimination t1/2 than the original
68Ga-
DOTAVAP-P1, although the difference was not statisti-
cally significant (Table 1).
Discussion
Previously, we have reported the feasibility of the VAP-
1-targeting peptide,
68Ga-DOTAVAP-P1, for PET ima-
ging of inflammation in different rat models [8-10].
However, as a limitation,
68Ga-DOTAVAP-P1 is cleared
very rapidly from circulation and its in vivo stability
against degradation by enzymes is only moderate. In
this study, we showed that the incorporation of a mini-
PEG spacer in
68Ga-DOTAVAP-P1 enhanced its in vivo
stability and improved the PET imaging of
inflammation.
The animal model used in our experiments involves
turpentine oil injection-induced subcutaneous inflamma-
tion as described previously [10]. In that study, we were
able to show that the H & E staining of the inflamed
site demonstrated infiltration of leucocytes and macro-
phages at the site of inflammation. The abscess centre
with few cells, including residual injected oil, exudates
and cell debris, was surrounded by an abscess wall. The
dermis also appeared to be inflamed. In the present
study, inflammation was evaluated in every animal by
visually observing the pale colour of inflamed subcuta-
neous tissue. We performed in vitro, ex vivo and in vivo
experiments to evaluate the VAP-1 targeting, inflamma-
tion imaging efficacy and pharmacokinetics of
68Ga-
DOTAVAP-PEG-P1 in comparison to the original
68Ga-
DOTAVAP-P1. The incorporation of a mini-PEG spacer
h a dn oa p p a r e n te f f e c to nt h ein vitro properties of the
VAP-1 binding peptide; both peptides were stable in
plasma incubations and their solubility was very similar.
However, when i.v. administered,
68Ga-DOTAVAP-
PEG-P1 showed significantly longer metabolic and
Figure 2 Biodistribution of the
68Ga-DOTA-peptides at 60 min after injection. Results are given as the mean ± SD of three experiments.
Asterisks indicate statistically significant differences between the peptides. *P < 0.05; **P < 0.01.
Figure 3 In vivo stability of the i.v. administered
68Ga-DOTA-
peptides in blood circulation of the rat. Results are given as the
means of three to seven experiments. NS, not significant; **P < 0.01;
***P < 0.001.
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pared to
68Ga-DOTAVAP-P1. Furthermore, our results
revealed that while both peptides were able to visualise
experimental inflammation by PET imaging,
68Ga-
DOTAVAP-PEG-P1 showed a higher inflammation-to-
muscle ratio than the original
68Ga-DOTAVAP-P1. As
regards
68Ga-DOTAVAP-P1, the results of this study
are in line with our previous publications [8-10]. The
renal excretion of
68Ga-DOTAVAP-PEG-P1 was slower,
resulting in a significantly lower urinary bladder radioac-
tivity in comparison to
68Ga-DOTAVAP-P1. The liver
uptake was rather high for both peptides, which is, at
least in part, due to the high number of VAP-1 recep-
tors in the sinusoidal endothelial cells in the liver [12].
Some degradation products of
68Ga-DOTA-peptides,
such as free
68Ga, also tend to accumulate in the liver
[13]. Although modification with a mini-PEG spacer
generally decreases liver uptake, the two peptides
behaved quite similarly in our study, suggesting a VAP-
1-specific binding in this tissue.
PEGylation has widely been used for improving the in
vivo kinetics of pharmaceuticals. However, the results of
such modifications depend much on the nature of the lead
compound and the choice of PEG linker [14-20]. In most
cases, PEGylation of radiopeptides has advantageous
effects, such as increased metabolic half-life, decreased
kidney uptake, and improved targeting and subsequent
improved targeting for high-quality imaging. However, dis-
advantageous results have also been reported, e.g. the
insertion of a long PEG chain may induce a higher liver
uptake and reduce receptor binding [16].
In this study, we incorporated an eight-carbon mini-
PEG spacer between the DOTA and the VAP-P1 pep-
tide in order to prolong its biological activity. The 8-
amino-3,6-dioxaoctanoic acid contains the shortest ether
structure possible of PEG with two ethylene oxide units.
A similar spacer has previously been used in imaging
agents by Burtea et al. [21], Ke et al. [22] and Silvola et
al. [23].
Modification with a mini-PEG spacer increased meta-
bolic stability of VAP-1-targeting DOTA-peptide. In
addition, it also improved in vivo imaging of inflamma-
tion suggesting that PEGylation had other highly pro-
nounced in vivo effects beyond modification of
pharmacokinetics. Althou g ht h em o d i f i c a t i o nw i t ha
mini-PEG spacer increased the target-to-background
ratio, the SUV values in the inflamed area were still very
low. Thus, further improvement of the tracer is
warranted.
Conclusion
The incorporation of a mini-PEG spacer enhanced the
in vivo stability and pharmacokinetics of the VAP-1-tar-
geting peptide, thus leading to higher target-to-back-
ground ratios and improved in vivo PET imaging of
experimental inflammation.
68Ga-DOTAVAP-PEG-P1
warrants further investigations for its feasibility in PET
imaging of inflammation.
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